ValuEngine upgraded shares of Intec Pharma (NASDAQ:NTEC) from a hold rating to a buy rating in a research report released on Monday, February 4th.
A number of other equities research analysts have also recently issued reports on the company. LADENBURG THALM/SH SH reiterated a buy rating and set a $12.00 price objective on shares of Intec Pharma in a research note on Tuesday, January 29th. Zacks Investment Research upgraded Intec Pharma from a sell rating to a hold rating in a research note on Saturday, January 26th. BidaskClub cut Intec Pharma from a strong-buy rating to a buy rating in a research note on Wednesday, January 16th. Finally, HC Wainwright restated a buy rating and issued a $16.00 price target on shares of Intec Pharma in a research note on Friday, January 4th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $11.96.
Shares of Intec Pharma stock traded down $0.04 on Monday, reaching $7.88. 21,856 shares of the company were exchanged, compared to its average volume of 163,684. Intec Pharma has a one year low of $3.55 and a one year high of $8.78. The stock has a market cap of $259.98 million, a P/E ratio of -4.78 and a beta of 0.39.
Intec Pharma (NASDAQ:NTEC) last announced its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Analysts forecast that Intec Pharma will post -1.31 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of NTEC. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Intec Pharma by 2,096.1% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 658,835 shares of the biotechnology company’s stock worth $3,722,000 after purchasing an additional 628,835 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Intec Pharma during the 4th quarter worth $2,972,000. Prosight Management LP grew its holdings in shares of Intec Pharma by 18.8% during the 3rd quarter. Prosight Management LP now owns 1,337,191 shares of the biotechnology company’s stock worth $7,555,000 after purchasing an additional 212,038 shares in the last quarter. ARK Investment Management LLC acquired a new stake in shares of Intec Pharma during the 3rd quarter worth $609,000. Finally, Laurion Capital Management LP acquired a new stake in shares of Intec Pharma during the 3rd quarter worth $532,000. 39.68% of the stock is currently owned by hedge funds and other institutional investors.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Further Reading: Do back-end load funds outperform no-load funds?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Intec Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intec Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.